{
    "id": 25552,
    "fullName": "KIT I571_D579dup",
    "impact": "duplication",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KIT I571_D579dup (also referred to as D579_H580insIDPTQLPYD) indicates the insertion of 9 duplicate amino acids, isoleucine (I)-571 through aspartic acid (D)-579, in the juxtamembrane domain (exon 11) of the Kit protein (PMID: 16226710). I571_D579dup has been identified in sequencing studies (PMID: 19768731, PMID: 23291969), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 13612,
                    "pubMedId": 19768731,
                    "title": "Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19768731"
                },
                {
                    "id": 648,
                    "pubMedId": 16226710,
                    "title": "Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16226710"
                },
                {
                    "id": 13613,
                    "pubMedId": 23291969,
                    "title": "Molecular characterization of an Italian series of sporadic GISTs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23291969"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "I571_D579dup",
    "createDate": "10/19/2016",
    "updateDate": "11/14/2019",
    "referenceTranscriptCoordinates": {
        "id": 136216,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54727479_54727505",
        "cDna": "c.1711_1737",
        "protein": "p.I571_D579",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Flumatinib in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 26586,
                "profileName": "KIT I571_D579dup"
            },
            "therapy": {
                "id": 3169,
                "therapyName": "Flumatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Gleevec (imatinib) in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 26586,
                "profileName": "KIT I571_D579dup"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Sutent (sunitinib) in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 26586,
                "profileName": "KIT I571_D579dup"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26586,
            "profileName": "KIT I571_D579dup",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136216,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54727479_54727505",
            "cDna": "c.1711_1737",
            "protein": "p.I571_D579",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136217,
            "transcript": "XM_017008178",
            "gDna": "chr4:g.54727479_54727505",
            "cDna": "c.1711_1737",
            "protein": "p.I571_D579",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}